Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | JMP bekräftigt Bewertung für GH Research nach positiven Ergebnissen eines Konkurrenten | - | Investing.com Deutsch | ||
Di | JMP reiterates GH Research stock rating on competitor's positive results | 1 | Investing.com | ||
20.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
20.06. | GH Research reicht Antwort auf FDA-Klinische Sperre für Depressionsmedikament ein | 1 | Investing.com Deutsch | ||
GH RESEARCH Aktie jetzt für 0€ handeln | |||||
20.06. | GH Research submits response to FDA clinical hold for depression drug | 1 | Investing.com | ||
20.06. | GH Research PLC: GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule | 89 | GlobeNewswire (Europe) | DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
13.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
04.06. | Cantor Fitzgerald behält Übergewichtung für GH Research-Aktie bei | 2 | Investing.com Deutsch | ||
27.05. | GH Research PLC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
15.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.05. | GH Research PLC: GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting | 62 | GlobeNewswire (Europe) | DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
08.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.05. | GH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates | 149 | GlobeNewswire (Europe) | Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents... ► Artikel lesen | |
03.03. | Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 | 6 | Insider Monkey | ||
01.03. | GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 | 2 | Insider Monkey | ||
27.02. | GH Research PLC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
27.02. | GH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business Updates | 191 | GlobeNewswire (Europe) | Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate... ► Artikel lesen | |
27.02. | GH Research PLC - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
27.02. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
26.02. | Stifel raises GH Research stock target to $32 on strong trial data | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,128 | -0,94 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
VALNEVA | 2,384 | -4,41 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
BIOFRONTERA | 2,200 | +0,92 % | Biofrontera AG: Verhandlungen mit Biofrontera Inc. gehen kommende Woche weiter | Bad Marienberg (www.anleihencheck.de) - Pressemitteilung der Biofrontera AG vom 26.06.2025:Die Verhandlungen zwischen der deutschen Biofrontera Gruppe und dem US-amerikanischen Unternehmen Biofrontera... ► Artikel lesen | |
BIOGEN | 108,70 | +0,23 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
ILLUMINA | 80,38 | -0,10 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
NANOREPRO | 1,620 | -2,41 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
OCUGEN | 0,909 | +3,81 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
VAXART | 0,441 | -3,67 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
CYTODYN | 0,258 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer | VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
IMMUNIC | 0,600 | -0,50 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
CEL-SCI | 2,425 | 0,00 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen | |
ADAPTIVE BIOTECHNOLOGIES | 10,185 | -2,02 % | Cathie Wood's ARK buys BWX stock, sells Adaptive Biotech | ||
BLUEPRINT MEDICINES | 109,20 | -0,23 % | Blueprint Medicines stock hits all-time high at 128.34 USD | ||
MUSTGROW BIOLOGICS | 0,487 | -3,37 % | MustGrow Biologics Corp. Announces Results of Shareholder Meeting | Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its... ► Artikel lesen | |
GENPREX | 1,820 | -100,00 % | Genprex, Inc. - 8-K, Current Report |